Correction to: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness

Alessandra di Gennaro; Valentina Damiano; Giulia Brisotto; Michela Armellin; Tiziana Perin; Antonella Zucchetto; Michela Guardascione; Herman P Spaink; Claudio Doglioni; B Ewa Snaar-Jagalska; Manuela Santarosa; Roberta Maestro

doi:10.1038/s41418-018-0249-6

Correction to: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness

Cell Death Differ. 2019 Nov;26(11):2493. doi: 10.1038/s41418-018-0249-6.

Affiliations

¹ Oncogenetics and Functional Oncogenomics Unit, CRO Aviano National Cancer Institute, via F. Gallini 2, Aviano, 33081 PN, Italy.
² Pathology Unit, CRO Aviano National Cancer Institute, Aviano (PN), via F. Gallini 2, Aviano, 33081 PN, Italy.
³ Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano (PN) via F. Gallini 2, Aviano, 33081 PN, Italy.
⁴ Medical Oncology Unit, CRO Aviano National Cancer Institute, via F. Gallini 2, Aviano, 33081 PN, Italy.
⁵ Molecular Cell Biology Department, Institute of Biology, Leiden University, Leiden, 2333CC, The Netherlands.
⁶ Ateneo Vita-Salute, Department of Pathology, IRCCS Scientific Institute San Raffaele, Milan, 20132, Italy.
⁷ Oncogenetics and Functional Oncogenomics Unit, CRO Aviano National Cancer Institute, via F. Gallini 2, Aviano, 33081 PN, Italy. msantarosa@cro.it.
⁸ Oncogenetics and Functional Oncogenomics Unit, CRO Aviano National Cancer Institute, via F. Gallini 2, Aviano, 33081 PN, Italy. rmaestro@cro.it.

Abstract

Since publication of the article, the authors were notified by ATCC that the cell line HCC1395 (ATCC® CRL-2324™ Lot 62235652) suffered a "low level of cell line cross-contamination" with another cell line.

Publication types

Published Erratum